Researchers say, we may need new vaccines especially against the delta variant

Preparations targeting the highly contagious delta variant may be needed, according to researchers in England for a large study of Covid-19 vaccines. A British study showed that the risk of developing the delta type ranged between 50 and 60 percent. Less in fully vaccinated people.

The third wave of English coronavirus cases was triggered by the delta variant. This applies to both people who are not immunized, especially those between the ages of 12 and 24, who have received vaccinations. This is the result of a study conducted on samples of 98 thousand. Residents of England, citing Bloomberg News.

Vaccines are less effective at containing infections 49 proc. With 64 proc. A month ago, the researchers noted. By contrast, vaccine protection against the development of Covid-19 symptoms has decreased 83 an act 59 percent.

The study authors said there is scientific evidence that the spiky protein of this type of Covid-19 has mutated to the point where current vaccines are less effective. And therefore, “The development of vaccines against the delta variant may be warranted (…)”.

Vaccines are imperfect, but it’s better than not getting them

The United States, Britain and Israel are among the most vaccinated countries in the world, yet there has been a sharp increase in the number of cases and hospitalizations associated with the delta variant everywhere, according to Bloomberg.

However, current vaccines still provide a relatively high degree of protection. Fully vaccinated individuals were three times less likely to be infected with deltavirus than unvaccinated individuals. According to a study conducted by several UK research institutions, people who have been fully vaccinated are less likely to develop symptoms of the disease or pass the virus on to others.

For example, researchers from Imperial College London note that among people who received two doses of the vaccine, the probability of testing positive for Covid-19 was half that. In people with symptoms of the disease, effectiveness increased to about 59 percent.